Studies have demonstrated that the presence of the BRAF V600E mutation is highly specific for malignancy, with specificity rates nearing 100% in some cohorts [6]. According to the 2015 American Thyroid Association (ATA) guidelines, BRAF mutation testing in AUS or follicular lesion of undetermined significance (FLUS) samples demonstrates high specificity but low sensitivity for cancer detection [7]. The gene discussed is BRAF; the disease is cancer.